問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
China Medical University Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
下載
2025-04-01 - 2029-09-30
Condition/Disease
The percentage change in proteinuria from baseline to week 36 was assessed based on the urine protein/creatinine ratio (UPCR) measurement of 24-hour urine samples.
Test Drug
Felzartamab
Participate Sites8Sites
Recruiting8Sites
2025-04-01 - 2030-06-18
Advanced hepatocellular carcinoma
Atezolizumab Bevacizumab Rilvegostomig (AZD2936) Tremelimumab
2019-12-01 - 2030-05-31
Participate Sites16Sites
Not yet recruiting4Sites
Recruiting12Sites
2019-01-25 - 2022-12-31
Participate Sites6Sites
Recruiting5Sites
2021-06-01 - 2031-12-24
Participate Sites5Sites
Not yet recruiting2Sites
Recruiting3Sites
2020-09-01 - 2027-06-30
Not yet recruiting1Sites
2021-02-01 - 2027-12-31
Recruiting6Sites
2019-02-01 - 2022-12-31
Participate Sites2Sites
Recruiting2Sites
2023-08-01 - 2032-06-30
Participate Sites7Sites
Recruiting7Sites
2025-02-03 - 2029-12-31
Participate Sites3Sites
全部
